<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02687932</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0938</org_study_id>
    <nct_id>NCT02687932</nct_id>
  </id_info>
  <brief_title>Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation</brief_title>
  <acronym>PRIME</acronym>
  <official_title>Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage B and C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional MR is caused by adverse left ventricular remodeling after myocardial injury and&#xD;
      associated with an increased incidence of heart failure and death. Because secondary&#xD;
      functional MR usually develops as a result of LV dysfunction, diuretics, beta blockers,&#xD;
      angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), and&#xD;
      aldosterone antagonists are given to patients with functional MR in line with the guidelines&#xD;
      in the management of heart failure. However, functional MR appears to remain common despite&#xD;
      use of these drugs and current medical treatment is usually insufficient for reducing MR or&#xD;
      reversing the adverse LV remodeling. As LCZ696 is a dual-acting inhibitor of the&#xD;
      renin-angiotensin-aldosterone system (RAAS) and neutral endopeptidase (NEP), LCZ696 has&#xD;
      greater hemodynamic and neurohormonal effects than ARB alone. Investigators try to examine&#xD;
      the hypothesis that LCZ696 is superior to ARB alone in improving functional MR in patients&#xD;
      with LV dysfunction and functional MR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional ischemic mitral regurgitation (MR) has been reported to occur in up to 40% of&#xD;
      patients after myocardial infarction, and the prevalence of functional MR is likely to&#xD;
      increase with an aging population and improved survival rates for myocardial infarction. The&#xD;
      presence of functional MR is associated with an increased incidence of heart failure and&#xD;
      death, and patients with significant functional MR incur about a two-fold increase in the&#xD;
      risk of mortality and about a four-fold increase in the risk of heart failure. Functional MR&#xD;
      is caused by adverse left ventricular remodeling after myocardial injury with enlargement of&#xD;
      the left ventricle (LV), apical and lateral displacement of papillary muscles, leaflet&#xD;
      tethering and reduced closing forces. The leaflets are normal in secondary functional MR and&#xD;
      the treatment is considerably different between functional and primary MR. Surgery is the&#xD;
      only definitive therapy for primary severe MR and primary MR can usually be cured by surgical&#xD;
      valve repair. However, surgical indications are unclear in severe functional MR, because&#xD;
      outcomes after surgery for functional MR remain suboptimum. Operative mortality, long-term&#xD;
      mortality and heart failure rates are still high in patients with severe functional MR&#xD;
      despite surgical improvements. According to the current guidelines, mitral valve surgery may&#xD;
      be considered only for severely symptomatic patients with severe secondary functional MR who&#xD;
      have persistent symptoms despite optimal medical therapy for heart failure.&#xD;
&#xD;
      Because secondary functional MR usually develops as a result of LV dysfunction, diuretics,&#xD;
      beta blockers, angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor&#xD;
      blockers (ARB), and aldosterone antagonists are given to patients with functional MR in line&#xD;
      with the guidelines in the management of heart failure. However, functional MR appears to&#xD;
      remain common despite use of these drugs and current medical treatment is usually&#xD;
      insufficient for reducing MR or reversing the adverse LV remodeling. Persistence of&#xD;
      functional MR due to the insufficient effectiveness of current medical treatment&#xD;
      significantly increases morbidity and mortality, and compared with surgical or percutaneous&#xD;
      revascularization, significantly higher mortality was observed in patients managed with&#xD;
      medical therapy.&#xD;
&#xD;
      Quantitative assessment of MR is strongly recommended in the guidelines and the regurgitant&#xD;
      volume and the effective regurgitant orifice area (EROA) of MR can be measured accurately and&#xD;
      reproducibly by Doppler echocardiography. The EROA of MR has an important prognostic value in&#xD;
      primary and secondary functional MR. Because functional MR carries an adverse prognosis with&#xD;
      a graded relationship between MR severity and reduced survival, therapies that induce&#xD;
      beneficial reverse remodeling of the LV and reduce MR, may improve survival. ACE inhibitors&#xD;
      and ARBs could partially attenuate LV dilatation and remodeling after myocardial injury, but&#xD;
      there are no published data from prospective trials regarding whether attenuation of&#xD;
      remodeling by ACE inhibitors or ARBs reduces functional MR.&#xD;
&#xD;
      LCZ696 is a dual-acting inhibitor of the renin-angiotensin-aldosterone system (RAAS) and&#xD;
      neutral endopeptidase (NEP). As LCZ696 offers the therapeutic advantages of concomitantly&#xD;
      blocking both RAAS and NEP, LCZ696 was more effective in reducing the risk of death from&#xD;
      cardiovascular causes or hospitalization for heart failure in patients with chronic heart&#xD;
      failure than ACE inhibitor. Because NEP is involved in the metabolism of a number of&#xD;
      vasoactive peptides such as natriuretic peptides, NEP inhibitor has vasodilating effects,&#xD;
      facilitates sodium excretion and has profound effects on LV remodeling. Trials of&#xD;
      hypertension and heart failure with a preserved ejection fraction also showed that LCZ696 had&#xD;
      greater hemodynamic and neurohormonal effects than ARB alone. To date, there has been no&#xD;
      proven pharmacological therapy to improve functional MR, and the development of medical&#xD;
      therapy should be at the forefront of research considering the limited role of surgery in&#xD;
      managing functional MR. Investigators hypothesize that LCZ696 is superior to ARB alone in&#xD;
      improving functional MR in patients with LV dysfunction and functional MR via synergistic&#xD;
      effects of NEP and RAAS inhibition on LV remodeling, and try to examine this hypothesis in a&#xD;
      multicenter, double-blind, randomized comparison study using echocardiography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">January 2, 2018</completion_date>
  <primary_completion_date type="Actual">January 2, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of effective regurgitant orifice area (EROA) of functional mitral regurgitation from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of regurgitant volume from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of left ventricular end-systolic volume from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of left ventricular end-diastolic volume from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of incomplete mitral leaflet closure area from baseline to 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Left Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>LCZ696</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valsartan for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <arm_group_label>LCZ696</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must agree to the study protocol and provide written informed consent&#xD;
&#xD;
          2. Outpatients â‰¥ 20 years of age, male or female&#xD;
&#xD;
          3. Patients with secondary functional MR (stage B and C) and LV dysfunction&#xD;
&#xD;
               -  Symptoms due to coronary ischemia or heart failure may be present but symptoms&#xD;
                  due to MR should be absent&#xD;
&#xD;
               -  Normal mitral valve leaflets and chords&#xD;
&#xD;
               -  Regional or global wall motion abnormalities with mild or severe tethering of&#xD;
                  leaflet&#xD;
&#xD;
               -  ERO &gt; 0.10 cm2&#xD;
&#xD;
               -  25% &lt; LV ejection fraction &lt; 50%&#xD;
&#xD;
          4. Dyspnea of NYHA functional class II or III&#xD;
&#xD;
          5. Patients must be on stable, optimized dose of an ACE inhibitors or ARBs for at least 4&#xD;
             weeks prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity or allergy to the study drug, drugs of similar chemical&#xD;
             classes, ARBs, or NEP inhibitors as well as known or suspected contraindications to&#xD;
             the study drug&#xD;
&#xD;
          2. Known history of angioedema&#xD;
&#xD;
          3. Any evidence of structural mitral valve disease, including prolapse of mitral leaflets&#xD;
             and rupture of chords or papillary muscles&#xD;
&#xD;
          4. Current acute decompensated heart failure or dyspnea of NYHA functional class IV&#xD;
&#xD;
          5. Medical history of hospitalization within 6 weeks&#xD;
&#xD;
          6. Symptomatic hypotension and/or a SBP &lt; 100 mmHg at screening&#xD;
&#xD;
          7. Estimated GFR &lt; 30 mL/min/1.73m2&#xD;
&#xD;
          8. Serum potassium &gt; 5 mmol/L at screening&#xD;
&#xD;
          9. Evidence of hepatic disease as determined by any one of the following: AST or ALT&#xD;
             values exceeding 2 x upper limit of normal (ULN) at screening visit (Visit 0), history&#xD;
             of hepatic encephalopathy, history of esophageal varices, or history of portacaval&#xD;
             shunt&#xD;
&#xD;
         10. Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months&#xD;
&#xD;
         11. Planned coronary revascularization or mitral valve intervention within 1 year&#xD;
&#xD;
         12. Heart transplantation or implantation of cardiac resynchronization therapy&#xD;
&#xD;
         13. History of severe pulmonary disease&#xD;
&#xD;
         14. Significant aortic valve disease&#xD;
&#xD;
         15. Primary aldosteronism&#xD;
&#xD;
         16. Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they are using a barrier method plus a hormonal method&#xD;
&#xD;
         17. Pregnant or nursing (lactating) women&#xD;
&#xD;
         18. Any clinically significant abnormality identified at the screening visit, physical&#xD;
             examination, laboratory tests, or electrocardiogram which, in the judgment of the&#xD;
             investigator, would preclude safe completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duk-Hyun Kang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Duk-Hyun Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Functional Mitral Regurgitation</keyword>
  <keyword>Ischemic Mitral Regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

